Q4 FY26 results analysis · June 17, 2026

Aster DM Healthcare Ltd Q4 FY26 Results Analysis: PAT Surges 77%, EBITDA Margin Expands 314 bps

+77.4%PAT year on year, Rs. 140.17 Cr
Cofacto ResearchPublished June 17, 20262 min readPositive read
Quick summary

Aster DM Healthcare Ltd's Q4 FY26 numbers came in strong, with revenue of Rs. 1,182.38 Cr (+18.20% YoY) and PAT growth of +77.39% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateApril 30, 2026
QuarterQ4 FY 2025-2026
Revenue (Q4)Rs. 1,182.38 Cr (+18.20% YoY)
PAT (Q4)Rs. 140.17 Cr (+77.39% YoY)
EBITDA margin19.70% (+314 bps YoY)
EPS (Q4)Rs. 2.72 (+71.07% YoY)
Market capRs. 39,149.00 Cr
CMPRs. 754.70

Quarter Snapshot

Aster DM Healthcare delivered strong Q4 FY26 results with 18.2% revenue growth and 77.4% PAT growth, driven by the Hospitals & Clinics segment. EBITDA margin expanded 314 bps YoY to 19.70%, and the company generated robust free cash flow of Rs.187 Cr. While the company met its revenue guidance at the lower end, the EBITDA margin target of 23-24% was missed, and the QCIL merger remains a key catalyst pending final NCLT approval.

Key Investment Insights

Key Positives

  • Revenue grew 18.2% YoY to Rs.1,182.38 Cr in Q4 FY26
  • PAT (owners, cont. ops) grew 77.4% YoY to Rs.140.17 Cr in Q4
  • EBITDA margin expanded 314 bps YoY to 19.70% in Q4
  • Hospitals & Clinics segment EBIT grew 40.9% YoY, with margin expansion of 281 bps to 17.9%
  • Operating cash flow was Rs.655.92 Cr for FY26, with CFO to PAT ratio of 1.69x
  • Free cash flow was positive at Rs.186.84 Cr for FY26

Risk Factors

  • Post-IndAS EBITDA margin of 18.7% for FY26 missed management's guidance of 23-24%
  • Wholesale Pharmacies segment revenue declined 23.3% YoY in Q4 and posted a small operating loss
  • Effective tax rate varied widely quarter-to-quarter, with Q4 showing a very low rate of 5.98%
  • Subsidiaries contributed 44% of revenue but only 31% of PAT, indicating lower profitability in subsidiaries

Ask about this

Ask Cofacto a question about this result. Answers cite filings and company data.

Companies on this page
Share on X · LinkedIn · WhatsApp

Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.